Literature DB >> 28803727

Elimination of Toxic Microsatellite Repeat Expansion RNA by RNA-Targeting Cas9.

Ranjan Batra1, David A Nelles1, Elaine Pirie1, Steven M Blue1, Ryan J Marina1, Harrison Wang1, Isaac A Chaim1, James D Thomas2, Nigel Zhang1, Vu Nguyen1, Stefan Aigner1, Sebastian Markmiller1, Guangbin Xia3, Kevin D Corbett4, Maurice S Swanson2, Gene W Yeo5.   

Abstract

Microsatellite repeat expansions in DNA produce pathogenic RNA species that cause dominantly inherited diseases such as myotonic dystrophy type 1 and 2 (DM1/2), Huntington's disease, and C9orf72-linked amyotrophic lateral sclerosis (C9-ALS). Means to target these repetitive RNAs are required for diagnostic and therapeutic purposes. Here, we describe the development of a programmable CRISPR system capable of specifically visualizing and eliminating these toxic RNAs. We observe specific targeting and efficient elimination of microsatellite repeat expansion RNAs both when exogenously expressed and in patient cells. Importantly, RNA-targeting Cas9 (RCas9) reverses hallmark features of disease including elimination of RNA foci among all conditions studied (DM1, DM2, C9-ALS, polyglutamine diseases), reduction of polyglutamine protein products, relocalization of repeat-bound proteins to resemble healthy controls, and efficient reversal of DM1-associated splicing abnormalities in patient myotubes. Finally, we report a truncated RCas9 system compatible with adeno-associated viral packaging. This effort highlights the potential of RCas9 for human therapeutics.
Copyright © 2017 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  ALS; CRISPR; Huntington’s disease; RNA-targeting Cas9; adeno-associated virus; gene therapy; microsatellite repeat expansion; minimal Cas9; myotonic dystrophy

Mesh:

Substances:

Year:  2017        PMID: 28803727      PMCID: PMC5873302          DOI: 10.1016/j.cell.2017.07.010

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  61 in total

Review 1.  Developments in RNA splicing and disease.

Authors:  Michael G Poulos; Ranjan Batra; Konstantinos Charizanis; Maurice S Swanson
Journal:  Cold Spring Harb Perspect Biol       Date:  2011-01-01       Impact factor: 10.005

Review 2.  Pharmacokinetics, biodistribution and cell uptake of antisense oligonucleotides.

Authors:  Richard S Geary; Daniel Norris; Rosie Yu; C Frank Bennett
Journal:  Adv Drug Deliv Rev       Date:  2015-02-07       Impact factor: 15.470

3.  Genetic variation at five trimeric and tetrameric tandem repeat loci in four human population groups.

Authors:  A Edwards; H A Hammond; L Jin; C T Caskey; R Chakraborty
Journal:  Genomics       Date:  1992-02       Impact factor: 5.736

Review 4.  Mechanisms of RNA-mediated disease.

Authors:  Jason R O'Rourke; Maurice S Swanson
Journal:  J Biol Chem       Date:  2008-10-28       Impact factor: 5.157

5.  Targeted degradation of sense and antisense C9orf72 RNA foci as therapy for ALS and frontotemporal degeneration.

Authors:  Clotilde Lagier-Tourenne; Michael Baughn; Frank Rigo; Shuying Sun; Patrick Liu; Hai-Ri Li; Jie Jiang; Andrew T Watt; Seung Chun; Melanie Katz; Jinsong Qiu; Ying Sun; Shuo-Chien Ling; Qiang Zhu; Magdalini Polymenidou; Kevin Drenner; Jonathan W Artates; Melissa McAlonis-Downes; Sebastian Markmiller; Kasey R Hutt; Donald P Pizzo; Janet Cady; Matthew B Harms; Robert H Baloh; Scott R Vandenberg; Gene W Yeo; Xiang-Dong Fu; C Frank Bennett; Don W Cleveland; John Ravits
Journal:  Proc Natl Acad Sci U S A       Date:  2013-10-29       Impact factor: 11.205

6.  Expansion of a novel CAG trinucleotide repeat in the 5' region of PPP2R2B is associated with SCA12.

Authors:  S E Holmes; E E O'Hearn; M G McInnis; D A Gorelick-Feldman; J J Kleiderlein; C Callahan; N G Kwak; R G Ingersoll-Ashworth; M Sherr; A J Sumner; A H Sharp; U Ananth; W K Seltzer; M A Boss; A M Vieria-Saecker; J T Epplen; O Riess; C A Ross; R L Margolis
Journal:  Nat Genet       Date:  1999-12       Impact factor: 38.330

7.  Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy.

Authors:  Rahul N Kanadia; Jihae Shin; Yuan Yuan; Stuart G Beattie; Thurman M Wheeler; Charles A Thornton; Maurice S Swanson
Journal:  Proc Natl Acad Sci U S A       Date:  2006-07-24       Impact factor: 11.205

8.  Programmable RNA Tracking in Live Cells with CRISPR/Cas9.

Authors:  David A Nelles; Mark Y Fang; Mitchell R O'Connell; Jia L Xu; Sebastian J Markmiller; Jennifer A Doudna; Gene W Yeo
Journal:  Cell       Date:  2016-03-17       Impact factor: 41.582

9.  Dynamic imaging of genomic loci in living human cells by an optimized CRISPR/Cas system.

Authors:  Baohui Chen; Luke A Gilbert; Beth A Cimini; Joerg Schnitzbauer; Wei Zhang; Gene-Wei Li; Jason Park; Elizabeth H Blackburn; Jonathan S Weissman; Lei S Qi; Bo Huang
Journal:  Cell       Date:  2013-12-19       Impact factor: 41.582

10.  OLego: fast and sensitive mapping of spliced mRNA-Seq reads using small seeds.

Authors:  Jie Wu; Olga Anczuków; Adrian R Krainer; Michael Q Zhang; Chaolin Zhang
Journal:  Nucleic Acids Res       Date:  2013-04-09       Impact factor: 16.971

View more
  99 in total

1.  Programmable RNA-Guided RNA Effector Proteins Built from Human Parts.

Authors:  Simone Rauch; Emily He; Michael Srienc; Huiqing Zhou; Zijie Zhang; Bryan C Dickinson
Journal:  Cell       Date:  2019-06-20       Impact factor: 41.582

Review 2.  Recent advances in molecular therapies for neurological disease: triplet repeat disorders.

Authors:  Pedro Gonzalez-Alegre
Journal:  Hum Mol Genet       Date:  2019-10-01       Impact factor: 6.150

3.  Biochemical characterization of RNA-guided ribonuclease activities for CRISPR-Cas9 systems.

Authors:  Max J Gramelspacher; Zhonggang Hou; Yan Zhang
Journal:  Methods       Date:  2019-06-20       Impact factor: 3.608

4.  Repeat-associated non-ATG (RAN) translation.

Authors:  John Douglas Cleary; Amrutha Pattamatta; Laura P W Ranum
Journal:  J Biol Chem       Date:  2018-09-13       Impact factor: 5.157

Review 5.  CRISPR Tools for Systematic Studies of RNA Regulation.

Authors:  Jesse Engreitz; Omar Abudayyeh; Jonathan Gootenberg; Feng Zhang
Journal:  Cold Spring Harb Perspect Biol       Date:  2019-08-01       Impact factor: 10.005

Review 6.  Programmable RNA manipulation in living cells.

Authors:  Yu Pei; Mingxing Lu
Journal:  Cell Mol Life Sci       Date:  2019-07-31       Impact factor: 9.261

Review 7.  RNA Splicing and Disease: Animal Models to Therapies.

Authors:  Matías Montes; Brianne L Sanford; Daniel F Comiskey; Dawn S Chandler
Journal:  Trends Genet       Date:  2018-11-19       Impact factor: 11.639

8.  Transcriptome Engineering with RNA-Targeting Type VI-D CRISPR Effectors.

Authors:  Silvana Konermann; Peter Lotfy; Nicholas J Brideau; Jennifer Oki; Maxim N Shokhirev; Patrick D Hsu
Journal:  Cell       Date:  2018-03-15       Impact factor: 41.582

Review 9.  Role of the C9ORF72 Gene in the Pathogenesis of Amyotrophic Lateral Sclerosis and Frontotemporal Dementia.

Authors:  Zongbing Hao; Rui Wang; Haigang Ren; Guanghui Wang
Journal:  Neurosci Bull       Date:  2020-08-29       Impact factor: 5.203

Review 10.  In vivo epigenome editing and transcriptional modulation using CRISPR technology.

Authors:  Cia-Hin Lau; Yousin Suh
Journal:  Transgenic Res       Date:  2018-10-04       Impact factor: 2.788

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.